← Leaderboards
Carlos Zarate
National Institute Of Mental Health
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Institute Of Mental Health
Same institution · by research overlap
Others in their field
Top investigators on “Mental Depression”
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$51,306,513
- Joseph J Mann · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc$39,648,249
- Boris Birmaher · University Of Pittsburgh At Pittsburgh$32,263,758
- Carol D. Ryff · University Of Wisconsin Madison$30,932,130
- Ned H Kalin · University Of Wisconsin-Madison$28,068,100
Research focus
Mental DepressionResponseMajor Depressive DisorderBipolar DisorderDepressive SymptomsAntidepressive AgentsPlacebosMood DisordersProtocols DocumentationKetamineGlutamatesGeneticBiological MarkersDouble-Blind MethodDoseResistanceMontgomery And Asberg Depression Rating ScaleInfusion ProceduresImageTreatment ResponseOutcome MeasureSymptomsFeeling SuicidalReporting
Grant awards (46)
Non-invasive Neuromodulation Unit (NNU)$6,375,643
ZIA · FY2025 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$4,806,737
ZIA · FY2025 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$4,806,737
ZIA · FY2025 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$3,366,147
ZIA · FY2024 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$3,366,147
ZIA · FY2024 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$3,364,910
ZIA · FY2023 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$3,364,910
ZIA · FY2023 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$3,821,054
ZIA · FY2022 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$3,821,054
ZIA · FY2022 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$3,729,109
ZIA · FY2021 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$3,729,109
ZIA · FY2021 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$3,019,176
ZIA · FY2020 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$3,019,176
ZIA · FY2020 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$4,558,392
ZIA · FY2019 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$2,454,519
ZIA · FY2019 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$4,711,455
ZIA · FY2018 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$2,536,937
ZIA · FY2018 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$3,741,574
ZIA · FY2017 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$2,014,694
ZIA · FY2017 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$4,198,428
ZIA · FY2016 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$2,260,692
ZIA · FY2016 · MH · contact PI
Glutamatergic Modulators for Rapid and Sustained Antidepressant Effect$3,606,404
ZIA · FY2015 · MH · contact PI
Neurobiology and Target Validation of Novel Therapeutic Agents in Mood Disorders$1,941,909
ZIA · FY2015 · MH · contact PI
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect$2,874,774
ZIA · FY2014 · MH · contact PI
Neurobiology and Target validation of novel therapeutic agents in mood disorders$958,258
ZIA · FY2014 · MH · contact PI
Cholinergic Modulation of Cognition and Emotion in Mood Disorders$718,694
ZIA · FY2014 · MH · contact PI
Efficacy of an Antiglutamatergic Agents in Treatment-Resistant Depression$239,564
ZIA · FY2014 · MH · contact PI
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect$2,688,794
ZIA · FY2013 · MH · contact PI
Neurobiology and Target validation of novel therapeutic agents in mood disorders$896,265
ZIA · FY2013 · MH · contact PI
Cholinergic Modulation of Cognition and Emotion in Mood Disorders$672,199
ZIA · FY2013 · MH · contact PI
Efficacy of an Antiglutamatergic Agents in Treatment-Resistant Depression$224,066
ZIA · FY2013 · MH · contact PI
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect$2,543,265
ZIA · FY2012 · MH · contact PI
Target validation of novel therapeutic agents in mood disorders$847,755
ZIA · FY2012 · MH · contact PI
Cholinergic Modulation of Cognition and Emotion in Mood Disorders$635,816
ZIA · FY2012 · MH · contact PI
Efficacy of an Antiglutamatergic Agents in Treament-Resistant Deprepression$211,939
ZIA · FY2012 · MH · contact PI
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect$2,305,189
ZIA · FY2011 · MH · contact PI
Target validation of novel therapeutic agents in mood disorders$768,396
ZIA · FY2011 · MH · contact PI
Cholinergic Modulation of Cognition and Emotion in Mood Disorders$576,297
ZIA · FY2011 · MH · contact PI
Efficacy of an Antiglutamatergic Agents in Treament-Resistant Deprepression$192,099
ZIA · FY2011 · MH · contact PI
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect$1,015,201
ZIA · FY2010 · MH · contact PI
Target validation of novel therapeutic agents in mood disorders$338,400
ZIA · FY2010 · MH · contact PI
Cholinergic Modulation of Cognition and Emotion in Mood Disorders$253,800
ZIA · FY2010 · MH · contact PI
Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression$84,600
ZIA · FY2010 · MH · contact PI
Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression$232,920
Z01 · FY2008 · MH · contact PI
Comb Dopamine Agonist & Select Serotonin Reuptake Inhibitor f/Trtmt of Depression$232,920
Z01 · FY2008 · MH · contact PI
A pharmacologic strategy to bring about rapid (next day) antidepressants effects$186,336
Z01 · FY2008 · MH · contact PI